{"disease":{"id":"migraine-with-or-without-aura","name":"migraine with or without aura"},"drugs":{"marketed":[{"drug_id":"rimegepant-75mg-every-other-day-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg every other day dosing","generic_name":"rimegepant-75mg-every-other-day-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":64,"revenue":"798","mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines."},{"drug_id":"rimegepant-75mg-orally-disintegrating-tablets-odt","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg Orally Disintegrating Tablets (ODT)","generic_name":"rimegepant-75mg-orally-disintegrating-tablets-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":51,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist."},{"drug_id":"rimegepant-75mg-daily-dosing","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75mg daily dosing","generic_name":"rimegepant-75mg-daily-dosing","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":53,"revenue":null,"mechanism":"Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides."},{"drug_id":"rimegepant-bhv3000","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant/BHV3000","generic_name":"rimegepant-bhv3000","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor (CGRPR)","drug_class":"pharmacological class not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-25-mg","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 25 MG","generic_name":"rimegepant-25-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"triptans","indication_name":"Acute treatment of migraine attacks with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Triptans","generic_name":"triptans","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serotonin 5-HT1B/1D receptors","drug_class":"Selective serotonin receptor agonists","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-75-mg-odt","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"rimegepant 75 mg ODT","generic_name":"rimegepant-75-mg-odt","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"CGRP receptors","drug_class":"CGRP receptor antagonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"rimegepant-for-acute-migraine-treatment","indication_name":"Acute treatment of migraine with or without aura in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant for acute migraine treatment","generic_name":"rimegepant-for-acute-migraine-treatment","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"calcitonin gene-related peptide receptor","drug_class":"calcitonin gene-related peptide receptor antagonist","quality_score":54,"revenue":null,"mechanism":"Rimegepant targets the calcitonin gene-related peptide receptor to treat acute migraine."}],"pipeline":[{"drug_id":"rimegepant-75-mg","indication_name":"Acute treatment of migraine with or without aura","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rimegepant 75 MG","generic_name":"rimegepant-75-mg","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Calcitonin gene-related peptide (CGRP) receptor","drug_class":"CGRP receptor antagonist (gepant)","quality_score":25,"revenue":null,"mechanism":"Rimegepant selectively antagonizes the calcitonin gene-related peptide (CGRP) receptor to block migraine pain signaling."}],"offLabel":[],"totalMarketed":8,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT03266588","title":"Open Label Safety Study in Acute Treatment of Migraine","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":3019,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07497854","title":"A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT03461757","title":"Trial in Adult Subjects With Acute Migraines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1811,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02867709","title":"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1686,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT02828020","title":"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1672,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03237845","title":"Safety and Efficacy in Adult Subjects With Acute Migraines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1499,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT03235479","title":"Safety and Efficacy Study in Adult Subjects With Acute Migraines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1485,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT02873221","title":"An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1254,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT02848326","title":"Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":834,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT01004263","title":"A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":674,"lead_sponsor_name":"Organon and Co","has_results":true},{"nct_id":"NCT06203873","title":"A Comparison of Biodegradable and Metal Occluders in Patients With PFO and Migraine","phase":"NA","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT07015125","title":"Evaluation of a Wearable Device for Acute Treatment of Migraines","phase":"NA","overall_status":"COMPLETED","enrollment_count":160,"lead_sponsor_name":"Hinge Health, Inc","has_results":false},{"nct_id":"NCT03338920","title":"Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Currax Pharmaceuticals","has_results":true},{"nct_id":"NCT06874361","title":"Cooling to Alleviate Migraine #3","phase":"NA","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Mi-Helper, Inc.","has_results":true},{"nct_id":"NCT03061734","title":"Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Allodynic Therapeutics, Inc","has_results":false},{"nct_id":"NCT06245902","title":"An Acute Migraine Factorial Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"Allodynic Therapeutics, Inc","has_results":false},{"nct_id":"NCT07292506","title":"The Impact of Acupuncture on Biomarkers of Brain Injury and Inflammatory Response in Migraine","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":75,"lead_sponsor_name":"University Medical Centre Ljubljana","has_results":false},{"nct_id":"NCT03194555","title":"The Preventive Treatment of Migraine With Low-Dose Naltrexone and Acetaminophen Combination","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Allodynic Therapeutics, Inc","has_results":true}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}